(Q30427266)

12 September 2017

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study (English)

1 reference

12 September 2017

1 reference

1 reference

14

Henry S Friedman

1 reference

12 September 2017

5

Patrick Y Wen

1 reference

12 September 2017

2

Timothy Cloughesy

1 reference

12 September 2017

4

Michael Prados

1 reference

12 September 2017

10

Nina Paleologos

1 reference

12 September 2017

8

Lauren E Abrey

1 reference

12 September 2017

James J Vredenburgh

1

1 reference

12 September 2017

Meghna Samant

3

1 reference

12 September 2017

Tom Mikkelsen

6

1 reference

12 September 2017

David Schiff

7

1 reference

12 September 2017

W K Alfred Yung

9

1 reference

12 September 2017

Martin K Nicholas

11

1 reference

12 September 2017

Randy Jensen

12

1 reference

12 September 2017

Asha Das

13

1 reference

12 September 2017

8 December 2010

1 reference

12 September 2017

1 reference

12 September 2017

15

1 reference

12 September 2017

12

1 reference

12 September 2017

1329-1334

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Use of corticosteroids in neuro-oncology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Response criteria for phase II studies of supratentorial malignant glioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227925

Medical management of patients with brain tumors

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21147867

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2010-0105

1 reference

12 September 2017

1 reference

12 September 2017

1 reference